Aquestive Therapeutics Inc., a Warren, N.J.-based company formerly known as Monosol Rx LLC, said a new settlement agreement reached with Par Pharmaceuticals Inc., of Woodcliff Lake, N.J., will allow Par and Intelgenx Technologies Corp., of Montreal, to launch their proposed generic version of Suboxone (buprenorphine and naloxone sublingual film) no earlier than Jan. 1, 2023.